Company intelligence / Profile preview

Sichuan Honghe Biotechnology Co., Ltd.

Nanchong, Sichuan, China

Ownership: Private
Development stage: Other

Overview

Sichuan Honghe Biotechnology is a private Chinese biotech company founded in 2021, focused on developing small molecule drugs for oncology and nervous system diseases. Its lead asset, (-)-B-Elemene/KH617, is in Phase 1 clinical trials for advanced malignant solid neoplasms and glioblastoma. Preclinical data suggest superior efficacy over existing treatments for glioblastoma. The company has received regulatory approval from both the National Medical Products Administration of China and the FDA to conduct clinical trials with KH617.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

KH617

Beyond the preview

Go deeper on Sichuan Honghe Biotechnology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sichuan Honghe Biotechnology Co., Ltd..